Arbor Biotechnologies: Mark Angelino
Mar 03, 2021
Arbor Biotechnologies has appointed Mark Angelino to its board of directors. Angelino has more than 20 years of expertise in working with numerous pharmaceutical companies, Arbor said. He was the cofounder and chief operating officer of Generation Bio from 2016 until 2021, and has also served as as senior vice president of pharmaceutical sciences and the rare disease franchise head at Bluebird Bio from 2012 until 2016. He also served as senior director of R&D and site head in Cambridge, Massachusetts for Baxter Healthcare from 2010 to 2012.